| Bryan Joseph Gicana De La Cruz, PT | |
|
865 Cypress Ave, Ridgewood, NY 11385-4724 | |
| (848) 667-0943 | |
| (848) 667-0943 |
| Full Name | Bryan Joseph Gicana De La Cruz |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 9 Years |
| Location | 865 Cypress Ave, Ridgewood, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053848028 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 041569 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rb Physical And Occupational Therapy, Pllc | 5294870226 | 215 |
News Archive
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
New research published in the Journal of Bone and Mineral Research has found that cognitive decline is linked with accelerated bone loss and an increased fracture risk in women.
As efforts to bring an outbreak of yellow fever in Angola under control continue, the World Health Organization is reminding all travellers to the country that they are required to receive the yellow fever vaccination and to have a valid certificate of vaccination to prove that they are protected from the disease and to prevent its further spread.
PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.
› Verified 7 days ago
| Provider Name | Rb Physical And Occupational Therapy, Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1790013282 PECOS PAC ID: 5294870226 Enrollment ID: O20100302000766 |
News Archive
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
New research published in the Journal of Bone and Mineral Research has found that cognitive decline is linked with accelerated bone loss and an increased fracture risk in women.
As efforts to bring an outbreak of yellow fever in Angola under control continue, the World Health Organization is reminding all travellers to the country that they are required to receive the yellow fever vaccination and to have a valid certificate of vaccination to prove that they are protected from the disease and to prevent its further spread.
PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.
› Verified 7 days ago
| Provider Name | Brooklyn Health Physical Therapy, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1811212848 PECOS PAC ID: 5698805083 Enrollment ID: O20100610001108 |
News Archive
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
New research published in the Journal of Bone and Mineral Research has found that cognitive decline is linked with accelerated bone loss and an increased fracture risk in women.
As efforts to bring an outbreak of yellow fever in Angola under control continue, the World Health Organization is reminding all travellers to the country that they are required to receive the yellow fever vaccination and to have a valid certificate of vaccination to prove that they are protected from the disease and to prevent its further spread.
PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bryan Joseph Gicana De La Cruz, PT 5211 79th St Fl 2, Elmhurst, NY 11373-4112 Ph: (848) 667-0943 | Bryan Joseph Gicana De La Cruz, PT 865 Cypress Ave, Ridgewood, NY 11385-4724 Ph: (848) 667-0943 |
News Archive
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
New research published in the Journal of Bone and Mineral Research has found that cognitive decline is linked with accelerated bone loss and an increased fracture risk in women.
As efforts to bring an outbreak of yellow fever in Angola under control continue, the World Health Organization is reminding all travellers to the country that they are required to receive the yellow fever vaccination and to have a valid certificate of vaccination to prove that they are protected from the disease and to prevent its further spread.
PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.
› Verified 7 days ago
Khashayar Yousefian, Physical Therapist Medicare: Medicare Enrolled Practice Location: 1670 George St Apt 2l, Ridgewood, NY 11385 Phone: 408-667-7548 | |
Redcore Physical Therapy And Rehabiitation Physical Therapist Medicare: Medicare Enrolled Practice Location: 311 St Nicholas Avenue, Suite E- Basement, Ridgewood, NY 11385 Phone: 718-509-9888 Fax: 718-509-6144 | |
Bhavna Rajesh Devnani, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 6805 Fresh Pond Rd, Ridgewood, NY 11385 Phone: 929-299-6505 | |
Stacie Malner, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1666 Hancock St, Ridgewood, NY 11385 Phone: 718-456-7588 | |
Jamelle Rosette Santos, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6805 Fresh Pond Rd, Ridgewood, NY 11385 Phone: 718-456-2545 Fax: 718-559-6784 | |
Ruchi Modi, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 6805 Fresh Pond Rd, Ridgewood, NY 11385 Phone: 718-456-2545 Fax: 718-559-6784 |